Chemical-Shift-Encoded MRI for Prostate Cancer

This trial aims to determine if a new imaging method, chemical shift-encoded MRI, matches the accuracy of a PET scan using the tracer 3'-Deoxy-3'-[18F]-fluorothymidine in detecting active bone marrow in men with advanced prostate cancer. The study uses both imaging techniques on the same day to compare their effectiveness. Men diagnosed with prostate cancer and scheduled to receive the treatment 177Lu-PSMA may be suitable candidates for this trial. As an Early Phase 1 trial, this research seeks to understand how the new imaging method functions in people, offering participants a chance to contribute to groundbreaking advancements in prostate cancer diagnostics.

The trial requires that you stop taking any medications that impact bone marrow, such as those that stimulate or suppress it. If you're on chemotherapy or certain radiotherapy, you need to wait 4 weeks before participating.

Research has shown that chemical-shift-encoded MRI (CSE-MRI) safely captures detailed images of the body's interior, similar to a regular MRI. Reports of major side effects are absent, and patients generally tolerate it well.

Fluorothymidine F-18 PET (FLT PET) is also considered safe. It uses a tiny amount of a radioactive substance to highlight active areas in the body. Studies indicate that this method usually has minimal side effects, with any negative reactions being rare and mild.

Researchers are excited about the Chemical-Shift-Encoded MRI technique because it offers a novel way to visualize and assess prostate cancer, potentially enhancing the accuracy of current imaging methods. Unlike traditional imaging techniques, such as standard MRI or CT scans, this method uses chemical-shift encoding to generate detailed maps of fat distribution, which could provide new insights into tumor characteristics and treatment responses. Additionally, the use of 3'-Deoxy-3'-[18F]-fluorothymidine (FLT) in PET scans helps in assessing the proliferation of bone marrow, giving a clearer picture of cancer activity. This dual approach could lead to more tailored treatment plans and better outcomes for patients with metastatic prostate cancer.

Research has shown that a new type of MRI, called chemical-shift-encoded MRI (CSE-MRI), is gaining popularity for its potential to detect prostate cancer. Some studies suggest that advanced imaging methods like CSE-MRI can help doctors better identify prostate cancer and determine if it has spread, which is crucial for selecting the right treatment. However, evidence remains insufficient, and further research is needed to assess its accuracy compared to other methods. In this trial, participants will undergo CSE-MRI to generate a fat fraction map, potentially offering insights into cancer activity. The hope is that CSE-MRI could match or surpass current imaging techniques, providing a non-invasive way to monitor cancer activity in patients.⁶⁷⁸⁹¹⁰